Pharmaceutical giant Novo Nordisk has turned to influential Black Americans in pursuit of what would be a lucrative victory.
Novo Nordisk has turned to influential Black Americans in pursuit of what would be a lucrative victory: having Medicare cover a new class of weight loss drugs, including the company’s highly sought Wegovy
Former CNN political commentator Roland Martin moderated the session. Black health experts who support Medicare coverage of drugs used to treat obesity served on the panel, including Fatima Cody Stanford, an associate professor of medicine at Harvard Medical School. Stanford is a specialist in obesity who has received consulting fees from Novo Nordisk.
Those activities are part of a broader Novo Nordisk campaign to shift the public narrative about obesity. They open a new window on drugmakers’ efforts to influence consumers and public policy. It would be a financial boon to Novo Nordisk and other drugmakers, including Eli Lilly, which is seeking FDA approval for a weight loss drug.
Wegovy is FDA-approved for weight loss in adults who have a body mass index of 30 or greater—the definition of adult obesity, according to the Centers for Disease Control and Prevention—or a BMI of at least 27 plus at least one weight-related medical condition, such as hypertension. It’s also approved for patients as young as 12 who are deemed obese.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks making the biggest moves premarket: UPS, Lucid, Beyond Meat, Novo Nordisk and moreChegg shares surge over 20% after beating revenue expectations and announcing AI-focused strategies integration.
Read more »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Read more »
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soarThe Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Read more »
Novo Nordisk and Eli Lilly Experience Significant Gains with New Weight Loss DrugsNovo Nordisk and Eli Lilly have seen substantial increases in their stock prices due to the success of a new class of weight loss drugs. Eli Lilly's GLP-1 drug Mounjaro has particularly performed well, leading to a surge of up to 18% in the company's stock after reporting better than expected second-quarter results and raising its 2023 guidance.
Read more »
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Read more »
Increases in Black Unemployment Particularly Impact Black Women, Experts WarnThe unemployment rate for Black women rose from 4.4% in April to 5.3% in May. Similarly, the unemployment rate for Black men increased from 4.5% to 5.6%, as reported by Michelle Holder, an associate professor of economics at John Jay College at City University of New York.
Read more »